P4640Comparison of clopidogrel with ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: interim analysis of COSTIC study

Introduction: Acute coronary syndrome (ACS) is one of the leading causes of mortality globally. Percutaneous coronary intervention (PCI) is a widely used technique to overcome this condition. However, PCI is associated with increased risk of thrombosis for which P2Y12 inhibitors like clopidogrel or ticagrelor in combination with aspirin are recommended. Purpose: To evaluate the short- and long-term effectiveness and safety of clopidogrel versus ticagrelor in Chinese ACS patients who have undergone PCI. Methods: A total of 3587 patients diagnosed with ACS undergoing PCI were included between August 2014 and January 2017 for this ongoing prospective, single-centre registry study (NCT03239067). The primary effectiveness endpoints were vascular death, myocardial infarction (MI) and stroke. Death due to all cause for the mentioned primary endpoints were reported as secondary endpoint. For the safety endpoint, Thrombolysis in Myocardial Infarction (TIMI) bleeding criteria was taken as a reference. KM survival curves were constructed to compare the effectiveness and safety between groups, accompanied by multivariate Cox regression models.